BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10210325)

  • 1. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods.
    Dworzak MN; Stolz F; Fröschl G; Printz D; Henn T; Fischer S; Fleischer C; Haas OA; Fritsch G; Gadner H; Panzer-Grümayer ER
    Exp Hematol; 1999 Apr; 27(4):673-81. PubMed ID: 10210325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotypic shift in the B-cell precursors from regenerating bone marrow samples: A critical consideration for measurable residual disease assessment in B-lymphoblastic leukemia.
    Chatterjee G; Sriram H; Ghogale S; Deshpande N; Khanka T; Panda D; Pradhan SN; Girase K; Narula G; Dhamane C; Malik NR; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2021 Jul; 100(4):434-445. PubMed ID: 32896101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL.
    Lúcio P; Parreira A; van den Beemd MW; van Lochem EG; van Wering ER; Baars E; Porwit-MacDonald A; Bjorklund E; Gaipa G; Biondi A; Orfao A; Janossy G; van Dongen JJ; San Miguel JF
    Leukemia; 1999 Mar; 13(3):419-27. PubMed ID: 10086733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: method and significance.
    Dworzak MN; Fritsch G; Panzer-Grümayer ER; Mann G; Gadner H
    Leuk Lymphoma; 2000 Jul; 38(3-4):295-308. PubMed ID: 10830736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection.
    Burnusuzov HA; Spasova MI; Murdjeva MA; Stoyanova AA; Mumdziev IN; Kaleva VI; Belcheva MI; Bosheva MN
    Folia Med (Plovdiv); 2016 Mar; 58(1):28-35. PubMed ID: 27383875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative phenotype mapping of normal vs. malignant pediatric B-lymphopoiesis unveils leukemia-associated aberrations.
    Dworzak MN; Fritsch G; Fleischer C; Printz D; Fröschl G; Buchinger P; Mann G; Gadner H
    Exp Hematol; 1998 Apr; 26(4):305-13. PubMed ID: 9546313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
    Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
    Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection.
    Weir EG; Cowan K; LeBeau P; Borowitz MJ
    Leukemia; 1999 Apr; 13(4):558-67. PubMed ID: 10214862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
    Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
    Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of residual leukemic cells by flow cytometry in childhood B-cell precursor acute lymphoblastic leukemia: verification of leukemic state by flow-sorting and molecular/cytogenetic methods.
    Øbro NF; Ryder LP; Madsen HO; Andersen MK; Lausen B; Hasle H; Schmiegelow K; Marquart HV
    Haematologica; 2012 Jan; 97(1):137-41. PubMed ID: 21933850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].
    Liu YR; Zhang LP; Chang Y; Cheng YF; Fu JY; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):302-5. PubMed ID: 16875577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Theunissen PMJ; Sedek L; De Haas V; Szczepanski T; Van Der Sluijs A; Mejstrikova E; Nováková M; Kalina T; Lecrevisse Q; Orfao A; Lankester AC; van Dongen JJM; Van Der Velden VHJ;
    Br J Haematol; 2017 Jul; 178(2):257-266. PubMed ID: 28419441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.
    Dworzak MN; Fritsch G; Fleischer C; Printz D; Fröschl G; Buchinger P; Mann G; Gadner H
    Leukemia; 1997 Aug; 11(8):1266-73. PubMed ID: 9264380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
    Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells.
    Kihira K; Chelakkot VS; Kainuma H; Okumura Y; Tsuboya N; Okamura S; Kurihara K; Iwamoto S; Komada Y; Hori H
    Int J Hematol; 2020 Dec; 112(6):795-806. PubMed ID: 32862292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
    Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
    Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
    Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
    Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.